SCHEMBL307520

SCHEMBL307520

O=C(c1ccccc1-c1ccccc1)C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.57
CES1 P23141 1/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
CHRNB2 P17787 2/20 0.50
CHRNB4 P30926 2/20 0.50
CHRNA3 P32297 2/20 0.50
CHRNA4 P43681 2/20 0.50
HNF4A P41235 1/20 0.48
HTT P42858 2/20 0.47
HDAC6 Q9UBN7 3/20 0.47
TSHR P16473 1/20 0.47
RECQL P46063 1/20 0.47
TACR1 P25103 2/20 0.47
FABP3 P05413 1/20 0.44
FABP4 P15090 1/20 0.44
FABP5 Q01469 1/20 0.44
TP53 P04637 1/20 0.44
ALDH1A1 P00352 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163372 0.94 CES1 (0.50) BCAT2CES1MEN1KMT2ASMN1; SMN2
SCHEMBL29035974 0.86 BCAT2 (0.55) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
SCHEMBL28774592 0.83 BCAT2 (0.61) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
Trifluoroacetic Acid SCHEMBL16720000 0.82 HNF4A (0.56) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
SCHEMBL13543201 0.82 BCAT2 (0.59) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
Trifluoroacetic Acid SCHEMBL1786045 0.79 BCAT2 (0.79) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
Trifluoroacetic Acid SCHEMBL31255509 0.79 BCAT2 (0.79) BCAT2MEN1KMT2ASMN1; SMN2CHRNB2
SCHEMBL16567335 0.79 AKR1C3 (0.47) CES1HTTHDAC6TACR1ALDH1A1
SCHEMBL18043680 0.79 PTGDR2 (0.47) CES1SMN1; SMN2HDAC6TSHRFABP4
SCHEMBL28361773 0.79 SLC6A2 (0.59) MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243310-A1 ANION EXCHANGE BRANCHED CO-POLYMER WITH POLY(ARYL) AND A BRANCHED COMPOUND AND QUINUCLIDINIUM SIDE CHAINS AND SYNTHESIS THEREOF USA FORTESCUE IP INC (US) 2025-07-31 US disclosed
US-12283729-B2 Anion exchange branched co-polymer with poly(aryl) and a branched compound and quinuclidinium side chains and synthesis thereof USA FORTESCUE IP INC (US) 2025-04-22 US disclosed
US-20250062377-A1 ANION EXCHANGE BRANCHED CO-POLYMER WITH POLY(ARYL) AND A BRANCHED COMPOUND AND QUINUCLIDINIUM SIDE CHAINS AND SYNTHESIS THEREOF USA FORTESCUE IP INC (US) 2025-02-20 US disclosed
WO-2024216181-A1 ANION EXCHANGE BRANCHED CO-POLYMER WITH POLY(ARYL) AND A BRANCHED COMPOUND AND QUINUCLIDINIUM SIDE CHAINS AND SYNTHESIS THEREOF USA Fortescue IP, Inc. (US) 2024-10-17 WO disclosed
CN-110862299-B Method for synthesizing 9-hydroxy-9 trifluoromethyl fluorene compound 浙江工业大学 2022-10-11 CN disclosed
CN-107324970-B Crosslinking agent and fluorine-containing aromatic compound 霓佳斯株式会社 2021-06-29 CN disclosed
CN-106574074-B Crosslinking agent and fluorine-containing aromatic compound 霓佳斯株式会社 2020-06-23 CN disclosed
CN-110862299-A Method for synthesizing 9-hydroxy-9 trifluoromethyl fluorene compound 浙江工业大学 2020-03-06 CN disclosed
EP-3187527-B1 CROSSLINKING AGENT AND FLUORINE-CONTAINING AROMATIC COMPOUND NICHIAS CORP (JP) 2019-10-30 EP disclosed
EP-2386547-B1 Multicyclic amino acid derivatives and methods of their use LEXICON PHARMACEUTICALS INC (US) 2018-06-20 EP disclosed
WO-2009009561-A1 METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION AND RELATED DISEASES AND DISORDERS LEXICON PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed
US-20090005382-A1 METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS TERSERA THERAPEUTICS LLC 2009-01-01 US disclosed
US-20090005381-A1 METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS LEXICON PHARMACEUTICALS, INC. 2009-01-01 US disclosed
WO-2009002964-A1 METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS LEXICON PHARMACEUTICALS, INC. (US) 2008-12-31 WO disclosed
WO-2009002970-A1 COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS LEXICON PHARMACEUTICALS, INC. (US) 2008-12-31 WO disclosed
EP-1984344-A2 MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE Lexicon Pharmaceuticals, Inc. (US) 2008-10-29 EP disclosed
WO-2008009815-A2 METHOD FOR PREPARING AROMATIC SULFONATES INSTITUT NATIONAL POLYTECHNIQUE DE GRENOBLE (FR) 2008-01-24 WO disclosed
WO-2008009816-A2 AROMATIC SULFINATES AND SULFONYL HALIDES, AND THE PREPARATION THEREOF INSTITUT NATIONAL POLYTECHNIQUE DE GRENOBLE (FR) 2008-01-24 WO disclosed
US-20070191370-A1 Multicyclic amino acid derivatives and methods of their use TERSERA THERAPEUTICS LLC 2007-08-16 US disclosed
WO-2007089335-A2 MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE LEXICON PHARMACEUTICAL INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191370-A1 Multicyclic amino acid derivatives and methods of their use AADAT, HNMT, TPH1 BCAT2 16/4885CES1 1312/4885MEN1 1261/4885
US-20090005381-A1 METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS TPH1, TPH2, HNMT BCAT2 677/4885CES1 558/4885MEN1 1824/4885
US-20090005382-A1 METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, MAOB BCAT2 405/4885CES1 286/4885MEN1 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.